Metronidazole- Versus Tinidazole-Based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
Key facts
- Who runs it
- University of Medicine and Pharmacy at Ho Chi Minh City
- Where
- Vietnam1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 600 people, planned
- Started
- 27 Jul 2026
- Expected to end
- 27 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Metronidazole
- Tinidazole 500mg
- tetracyline
- Bismuth Subcitrate
- esomeprazole 40 mg
- Record updated
- 5 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adults aged 18 years or older
- Confirmed Helicobacter pylori infection
- Willing and able to provide written informed consent
Who cannot take part
- Previous H. pylori eradication therapy
- Previous gastric surgery
- Use of antibiotics within the previous 4 weeks
- Gastrointestinal malignancy
- Stage IV or V chronic kidney disease
- Known allergy to any study medication
- Pregnancy or breastfeeding
- Liver cirrhosis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized, open-label clinical trial will compare two bismuth-containing quadruple therapies for the first-line treatment of Helicobacter pylori infection. Adults aged 18 years or older with confirmed H. pylori infection who have not previously received eradication treatment will be randomly assigned in a 1:1 ratio to receive either a metronidazole-based regimen or a tinidazole-based regimen for 14 days. Both regimens will also include esomeprazole, tetracycline, and bismuth subcitrate.
Read full original descriptionShow less
The main purpose of the study is to determine whether the tinidazole-based regimen is not inferior to the metronidazole-based regimen in achieving successful H. pylori eradication. Eradication will be assessed after treatment using a carbon-13 urea breath test or an endoscopic urease test. The study will also compare adverse effects and treatment tolerability between the two groups. The results may help clinicians select the more appropriate nitroimidazole for bismuth quadruple therapy in routine clinical practice.
The 2 groups in the trial
- Metronidazole-Based Bismuth Quadruple TherapyExisting treatment, for comparison
Treatment: Metronidazole, tetracyline, Bismuth Subcitrate, and esomeprazole 40 mg
- Tinidazole-Based Bismuth Quadruple TherapyTreatment being tested
Treatment: Tinidazole 500mg, tetracyline, Bismuth Subcitrate, and esomeprazole 40 mg
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison of Metronidazole- and Tinidazole-Based Bismuth Quadruple Regimens for Helicobacter Pylori Eradication
- Record updated
- 5 August 2026